Marcum Wealth LLC Makes New $201,000 Investment in Hologic, Inc. (NASDAQ:HOLX)

Marcum Wealth LLC purchased a new position in shares of Hologic, Inc. (NASDAQ:HOLXFree Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,578 shares of the medical equipment provider’s stock, valued at approximately $201,000.

Several other hedge funds have also made changes to their positions in HOLX. McGlone Suttner Wealth Management Inc. purchased a new stake in Hologic in the fourth quarter valued at approximately $27,000. Massmutual Trust Co. FSB ADV grew its stake in shares of Hologic by 69.4% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock valued at $40,000 after buying an additional 227 shares during the period. Allworth Financial LP increased its holdings in shares of Hologic by 39.3% during the 4th quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 179 shares during the last quarter. Mather Group LLC. purchased a new position in shares of Hologic in the 1st quarter worth $48,000. Finally, Livforsakringsbolaget Skandia Omsesidigt boosted its holdings in Hologic by 145.3% in the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 790 shares of the medical equipment provider’s stock valued at $56,000 after acquiring an additional 468 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Price Performance

HOLX stock opened at $73.07 on Friday. The stock’s 50 day moving average is $74.59 and its two-hundred day moving average is $74.13. Hologic, Inc. has a 52-week low of $64.02 and a 52-week high of $82.45. The company has a market capitalization of $17.05 billion, a PE ratio of 37.28, a P/E/G ratio of 2.40 and a beta of 1.00. The company has a quick ratio of 3.29, a current ratio of 3.97 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLXGet Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.05. Hologic had a net margin of 11.78% and a return on equity of 18.91%. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1 billion. During the same quarter in the previous year, the firm earned $1.06 earnings per share. The business’s revenue was down .8% compared to the same quarter last year. Analysts predict that Hologic, Inc. will post 4.08 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have weighed in on HOLX shares. Evercore ISI lifted their price target on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research report on Thursday, April 4th. Argus upped their price target on shares of Hologic from $89.00 to $95.00 and gave the stock a “buy” rating in a research report on Thursday, May 9th. JPMorgan Chase & Co. boosted their price objective on Hologic from $85.00 to $91.00 and gave the stock an “overweight” rating in a research note on Friday, May 3rd. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and increased their target price for the company from $80.00 to $95.00 in a research note on Wednesday, April 3rd. Finally, StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Hologic presently has an average rating of “Moderate Buy” and an average price target of $85.60.

View Our Latest Research Report on Hologic

Hologic Profile

(Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Recommended Stories

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLXFree Report).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.